More than 13,000 physicians in 24 specialty groups recognized Merck as having the best overall reputation among pharmaceutical companies, according to a new report from IMS America, Somerset, NJ, and the Plymouth Group, Plymouth Meeting, PA.
More than 13,000 physicians in 24 specialty groups recognized Merck as having the best overall reputation among pharmaceutical companies, according to a new report from IMS America, Somerset, NJ, and the Plymouth Group, Plymouth Meeting, PA.
Merck was also named best overall company by doctors in nine individual specialties, including general and family practitioners, internists, general surgeons, infectious disease specialists, cardiologists, nephrologists, orthopedic surgeons, rheumatologists and urologists.
The recent launches of three major products - Cozaar, Fosamax and Proscar - were influential in securing Merck its win. The growing popularity of its drugs Zocor and Vasotec may have factored in the report's results as well.
Companies were judged according to four attributes: research and development efforts, product line, educational programs and value-added services.
Physicians also evaluated the performances of pharmaceutical sales forces by their knowledge, professional style, service and sample availability.
The combined response from the 24: Astra-Merck's sales force took top honors among all physicians in every one of the four evaluation categories. It was also named by physicians as one of the two most familiar sales forces. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.